GlassScriptPhysician profile
Robert G Morgan
NPI 1932468071
$2,937.66
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,713 · 2020: $142 · 2021: $82.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,176.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,102.23 | 2019 | |
| Pfizer INC. | $283.44 | 2019-2021 | |
| Tris Pharma INC | $146.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.58 | 2019-2021 | |
| Cranial Technologies, INC | $39.20 | 2019 | |
| Ironshore Pharmaceuticals INC. | $37.77 | 2019 | |
| Glaxosmithkline, LLC. | $26.90 | 2019-2020 | |
| Sobi, INC | $22.79 | 2020 | |
| Phadia US INC. | $19.72 | 2019 | |
| Sanofi Pasteur INC. | $17.34 | 2019 | |
| Neos Therapeutics, LP | $12.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.